Bicara Therapeutics Expands Management Team with the Appointment of David Raben, M.D., as Chief Medical Officer

2023-07-24
高管变更免疫疗法
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the appointment of David Raben, M.D., as chief medical officer. Dr. Raben joins Bicara with more than 25 years of biopharma and academic translational oncology experience, having most recently served as vice president of global product development and product general manager, oncology, at Amgen. “David brings extensive oncology drug development experience to Bicara, including in the area of
head and neck cancer
, and we are thrilled to welcome him to our team,” said Claire Mazumdar, Ph.D., MBA, chief executive officer of Bicara Therapeutics. “This is an exciting time for Bicara following our recent ASCO presentation of positive interim data from our Phase 1/1b study of BCA101 in
HPV-negative, recurrent/metastatic head and neck squamous cell carcinoma
, and we believe David’s expertise will help propel Bicara as we continue to execute in the clinic and enter our next phase of growth.” “Bicara’s dual-action approach to treat
solid tumors
and compelling clinical data presents a unique opportunity to be part of an exciting company that has the potential to make a significant impact for people living with
cancer
,” said Dr. Raben. “I look forward to helping advance Bicara’s first-in-class bifunctional
EGFR
/TGF-β Inhibitor
TGF-β
Inhibitor, BCA101, in clinical development for
head and neck cancer
and other
solid tumors
, as well as the company’s additional pipeline programs.” Dr. Raben is a board-certified radiation oncologist. In his most recent role as vice president in oncology development at Amgen, his work centered on driving the anti-
DLL3
program in
neuroendocrine cancers
. Prior to Amgen, Dr. Raben served as vice president and franchise leader, clinical development oncology, at Genentech, where his work centered around precision medicine and immunotherapy trials in head and neck and thoracic cancer, in both late-stage and locally advanced settings. Dr. Raben has spent more than 20 years as a professor and an associate member of the University of Colorado Cancer Center
Cancer
Center, where his main areas of focus have been evaluating and combining novel biologic therapies in the laboratory and in clinical trials for patients with
locally advanced cancers of the head and neck
and lung. About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to combine the precision of well validated,
tumor
-targeting antibodies with the power of
tumor
microenvironment modulators. The company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the
tumor
microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the
tumor
. Bicara’s lead product candidate, BCA101, is a first-in-class
EGFR
/TGF-β-trap bifunctional antibody currently being evaluated in a Phase 1/1b study. For more information, please visit or follow us on LinkedIn or Twitter.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
头颈部肿瘤,复发性头颈部鳞状细胞癌,实体瘤
[+3]
靶点
EGFR,TGF-β,DLL3
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。